[1] Chandra RS,Orazem J,Ubben D,et al. Creative solutions to extraordinary challenges in clinical trials:methodology of a phase Ⅲ trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa[J]. Malar J, 2013, 12:122. [2] World Health Organization. World malaria report 2015[R]. Geneva:WHO, 2015. [3] Mita T,Tanabe K. Evolution of Plasmodium falciparum drug resistance:implications for the development and containment of artemisinin resistance[J]. Jpn J Infect Dis,2012,65(6):465-475. [4] Picot S,Olliaro P,de Monbrison F,et al. A systematic review and Meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria[J]. Malar J, 2009, 8:89. [5] Mungthin M,Suwandittakul N,Chaijaroenkul W,et al. The patterns of mutation and amplification of Plasmodium falciparum Pfcrt and pfmdr1 genes in Thailand during the year 1988 to 2003[J]. Parasitol Res, 2010, 107(3):539-545. [6] Dajem SMB,Al-Qahtani A. Analysis of gene mutations involved in chloroquine resistance in Plasmodium falciparum parasites isolated from patients in the southwest of Saudi Arabia[J]. Ann Saudi Med, 2010, 30(3):187-192. [7] Wellems TE, Panton LJ, Gluzman HY, et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross[J]. Nature, 1990, 345(6272):253-255. [8] Wellems TE,Walker-Jonah A,Panton LJ. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7[J]. Proc Natl Sci USA, 1991, 88(8):3382-3386. [9] 汤林华. 输入性疟疾的诊治与管理[M]. 上海:上海科学技术出版社, 2010:30-45. [10] 周水茂,杨燕,吴凯,等. 非洲输入性恶性疟病例裂殖子表面蛋白1等位基因型检测[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(4):247-250. [11] 周水茂,杨燕,陈智,等. 输入性恶性疟原虫Pfcrt基因76位点多态性分析[J]. 中国血吸虫病防治杂志, 2013, 25(4):402-404. [12] 张丽,丰俊,张少森,等. 2015年全国疟疾疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(6):477-481. [13] 郭传坤,黎军,林康明,等. 广西2010-2012年输入性疟疾流行病学分析[J]. 中国媒介生物学及控制杂志, 2014, 25(4):333-336. [14] 王亚丽,王煊,张彦平. 2005-2013年全国本地感染与境外输入疟疾流行病学特征分析[J]. 中国媒介生物学及控制杂志, 2015, 26(2):120-126. [15] 官亚宜,汤林华. 恶性疟原虫药物抗性相关的分子标记及其在药物抗性监测中的应用[J]. 中国寄生虫学与寄生虫病杂志, 2005, 23(2):117-120. [16] 张逸龙,潘卫庆. 恶性疟原虫对青蒿素产生抗性的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(6):418-424. [17] 王珊珊,董莹,邓艳,等. 中缅边境恶性疟原虫pfmdr1基因多态性及pfmsp1等位基因分型研究[J]. 国际医学寄生虫病杂志, 2012, 39(2):85-88. [18] Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, et al. Increased prevalence of the Plasmodium falciparum pfmdr1 86N genotype among field isolates from Franceville,Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine[J]. Infect Genet Evol, 2011, 11(2):512-517. [19] Mawili-Mboumba DP,Kun JF,Lell B,et al. Pfmdr1 alleles and response to ultralow-dose mefloquine treatment in Gabonese patients[J]. Antimicrob Agents Chemother,2002,46(1):166-170. [20] World Health Organization. Guidelines for the treatment of malaria[R]. Geneva:WHO, 2006. [21] Mawili-Mboumba DP,Ngomo JMN,Maboko F,et al. Pfcrt 76T and pfmdr1 86Y allele frequency in Plasmodium falciparum isolates and use of self-medication in a rural area of Gabon[J]. Trans R Soc Trop Med Hyg, 2014, 108(11):729-734. [22] Holmgren G,Hamrin J,Svärd J,et al. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa[J]. Infect Genet Evol, 2007, 7(5):562-569. [23] Lobo E,de Sousa B,Rosa S,et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy[J]. Malar J, 2014, 13:300. [24] Thomas SM,Ndir O,Dieng T,et al. In vitro chloroquine susceptibility and PCR analysis of Pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal[J]. Am J Trop Med Hyg, 2002, 66(5):474-480. [25] 徐超,魏庆宽,李瑾,等. 输入性恶性疟原虫耐药相关基因Pfcrt和pfmdr1单倍型及突变分析[J]. 中国人兽共患病学报, 2016, 32(12):1051-1057. [26] 周瑞敏,王轶南,钱丹,等. 2015年河南省输入性恶性疟原虫Pfcrt基因的多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(5):399-404. [27] 邓艳,王珊珊,董莹,等. 中缅边境恶性疟原虫Pfcrt基因76位点突变研究[J]. 中国人兽共患病学报, 2014, 30(11):1137-1140. |